Bolt Biotherapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 13, 2026, disclosing a net loss of $4.422 million for the third quarter and an accumulated deficit of $480.328 million.

Key Highlights

  • Net loss (Q3 2026): $4.422 million, compared to $7.144 million in Q3 2025, according to the filing.
  • Nine-month net loss: $19.549 million for the nine months ended September 30, 2026, versus $26.745 million for the same period in 2025.
  • Cash and cash equivalents: $13.782 million as of September 30, 2026, up from $11.703 million at December 31, 2025.
  • Total stockholders' equity: Declined to $8.562 million at September 30, 2026, from $26.505 million at December 31, 2025.
  • Collaboration revenue: $0 for Q3 2026, compared to $2.169 million in Q3 2025; $31 thousand for the nine months ended September 30, 2026.
  • Shares outstanding: 2,607,490 shares of common stock as of November 6, 2026, as reported by the registrant.
  • Impairment charges: $808 thousand recorded in the nine months ended September 30, 2026, with no comparable charge in the prior-year period.

Bolt Biotherapeutics Reports Reduced Operating Expenses and Declining Revenue for Q3 2026

According to the filing, Bolt Biotherapeutics (NASDAQ:BOLT) reported total operating expenses of $4.730 million for the three months ended September 30, 2026, a decrease from $9.872 million in the same quarter of 2025. Research and development expenses fell to $2.209 million from $6.535 million year over year, and general and administrative expenses declined to $2.521 million from $3.337 million. The company reported no collaboration revenue in Q3 2026, compared to $2.169 million in Q3 2025.

For the nine months ended September 30, 2026, the filing disclosed a loss from operations of $20.705 million, compared to $29.028 million for the same period in 2025. Total other income, net, was $1.156 million for the nine-month period, reflecting $599 thousand in net interest income and $557 thousand in other income. The net loss per share, basic and diluted, was $2.25 for Q3 2026 and $10.09 for the nine months ended September 30, 2026, based on weighted-average shares outstanding of 1,966,084 and 1,936,954, respectively.

The balance sheet as of September 30, 2026, showed total assets of $35.591 million, down from $56.748 million at December 31, 2025, primarily reflecting a reduction in short-term investments from $15.802 million to $1.016 million. The accumulated deficit grew to $480.328 million from $460.779 million at year-end 2025. The filing also noted stock-based compensation of $1.603 million for the nine-month period, and $808 thousand in asset impairment charges with no comparable amount in the prior year.

What Was Disclosed

Bolt Biotherapeutics filed its Form 10-Q for the quarter ended September 30, 2026, disclosing a third-quarter net loss of $4.422 million, zero collaboration revenue, reduced operating expenses versus 2025, and total stockholders' equity of $8.562 million.